IJRR

International Journal of Research and Review

| Home | Current Issue | Archive | Instructions to Authors | Journals |

Review Article

Year: 2023 | Month: April | Volume: 10 | Issue: 4 | Pages: 533-538

DOI: https://doi.org/10.52403/ijrr.20230466

Review on Concomitant use of Proton Pump Inhibitors [PPI] with Antiplatelet Agents

Husna T1, Manju CS2, Hasna Moideen3, Pavithra J4, Anjitha Chandrabose5

1Department of Pharmacy Practice, 2College of Pharmaceutical Sciences Govt. Medical College Kozhikode,
Kuhs University, Kozhikode, India

Corresponding Author: Manju CS

ABSTRACT

Clopidogrel and proton pump inhibitors (PPI) are the two drugs which are commonly used in clinical settings. clopidogrel is an anti-platelet drug   used for cardiovascular and cerebrovascular disease. The main drawback of long-term use of antiplatelet therapy is gastrointestinal bleeding so that the patients with antiplatelet drug is prescribed with proton pump inhibitors as a prophylactic measure.
Many studies suggest that proton pump inhibitors can reduce the antiplatelet effect of clopidogrel by inhibiting the enzyme CYP450.clopidogrel is a prodrug which is converted to active drug mainly by CYP2C19 in the liver. The same enzyme is responsible for the metabolism of proton pump inhibitors. Hence there is a possibility of interaction between clopidogrel and proton pump inhibitors. As a result, there is a chance of increasing cardiovascular events in patient taking proton pump inhibitors along with clopidogrel.

Keywords: [proton pump inhibitors, clopidogrel, gastrointestinal bleeding, prodrug, CYP450 enzyme, interaction]

[PDF Full Text]